Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Exclusion Criteria

• •Prior cerebrovascular event.
• •PCI within 30 days.
• •Hemodynamic instability.
• •On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis).
• •Hypersensitivity to Aspirin, Clopidogrel, or Prasugrel.
• •Known hematologic malignancies or thrombocytopenia (platelet count \<80x106/mL).
• •Known hemoglobinopathies or anemia (hemoglobin \<9 g/dL)
• •Pregnant and breastfeeding women \[women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\].